Pharmaceutical

Constellation Pharmaceuticals (Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced several planned updates to the Phase 2 portion of its ongoing MANIFEST study, an open-label Phase 1/2 clinical trial of its BET inhibitor CPI-0610 in MF. As quoted in the press release: MANIFEST is evaluating CPI-0610, …

Constellation Pharmaceuticals (Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced several planned updates to the Phase 2 portion of its ongoing MANIFEST study, an open-label Phase 1/2 clinical trial of its BET inhibitor CPI-0610 in MF.

As quoted in the press release:

MANIFEST is evaluating CPI-0610, either as a monotherapy or in combination with ruxolitinib, in patients with MF who are refractory or intolerant or have relapsed or lost response to the standard of care. Based on encouraging preliminary data in this trial, Constellation is amending the design of each second-line cohort to stratify all patients enrolled in the study based on transfusion dependence status. In addition, the Company is amending the design of MANIFEST to include a third cohort designed to evaluate treatment with CPI-0610 in combination with ruxolitinib as a first-line therapy in JAK 1/2-inhibitor-naïve MF patients.

The Company made these updates based on the unmet medical need for disease-modifying therapies in myelofibrosis, especially among patients requiring red-blood-cell transfusions. The changes are intended to enhance the clinical trial design by providing additional measures of potential clinical benefit and to expand the potential addressable patient population for CPI-0610.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20302.82+120.90
TSXV709.12+3.54
DOW31422.85+169.72
S&P 5003934.14+33.35
NASD11507.91+119.41
ASX7064.50-118.20

COMMODITIES

Commodities
Gold1838.46-3.71
Silver21.80-0.10
Copper4.30+0.02
Palladium2005.00+1.00
Platinum960.00+1.00
Oil112.72+0.51
Heating Oil3.65-0.02
Natural Gas8.05-0.26

DOWNLOAD FREE REPORTS

×